KZR Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Kezar Life Sciences, Inc.'s net margin of -255.85%. Kezar Life Sciences, Inc.'s return on equity of -58.35% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Kezar Life Sciences, Inc. has a consensus price target of $6.00, signalling downside risk potential of -4%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -22.02%. Given that NovaBay Pharmaceuticals, Inc. has more downside risk than Kezar Life Sciences, Inc., analysts believe Kezar Life Sciences, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Kezar Life Sciences, Inc. has a beta of 0.505, which suggesting that the stock is 49.462% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

Kezar Life Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Kezar Life Sciences, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Kezar Life Sciences, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Kezar Life Sciences, Inc.'s net income of -$11.2M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Kezar Life Sciences, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 1.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kezar Life Sciences, Inc. is -- versus 2.12x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics, Inc. has a net margin of -- compared to Kezar Life Sciences, Inc.'s net margin of --. Kezar Life Sciences, Inc.'s return on equity of -58.35% beat Oragenics, Inc.'s return on equity of -509.23%.

Kezar Life Sciences, Inc. has a consensus price target of $6.00, signalling downside risk potential of -4%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 134.85%. Given that Oragenics, Inc. has higher upside potential than Kezar Life Sciences, Inc., analysts believe Oragenics, Inc. is more attractive than Kezar Life Sciences, Inc..

Kezar Life Sciences, Inc. has a beta of 0.505, which suggesting that the stock is 49.462% less volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.

Kezar Life Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kezar Life Sciences, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.

Kezar Life Sciences, Inc. quarterly revenues are --, which are smaller than Oragenics, Inc. quarterly revenues of --. Kezar Life Sciences, Inc.'s net income of -$11.2M is lower than Oragenics, Inc.'s net income of -$3.1M. Notably, Kezar Life Sciences, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kezar Life Sciences, Inc. is -- versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Kezar Life Sciences, Inc.'s net margin of --. Kezar Life Sciences, Inc.'s return on equity of -58.35% beat Palatin Technologies's return on equity of --.

Kezar Life Sciences, Inc. has a consensus price target of $6.00, signalling downside risk potential of -4%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Kezar Life Sciences, Inc., analysts believe Palatin Technologies is more attractive than Kezar Life Sciences, Inc..

Kezar Life Sciences, Inc. has a beta of 0.505, which suggesting that the stock is 49.462% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

Kezar Life Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kezar Life Sciences, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Kezar Life Sciences, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Kezar Life Sciences, Inc.'s net income of -$11.2M is higher than Palatin Technologies's net income of --. Notably, Kezar Life Sciences, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kezar Life Sciences, Inc. is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics, Inc. has a net margin of -- compared to Kezar Life Sciences, Inc.'s net margin of --. Kezar Life Sciences, Inc.'s return on equity of -58.35% beat Theriva Biologics, Inc.'s return on equity of -171.04%.

Kezar Life Sciences, Inc. has a consensus price target of $6.00, signalling downside risk potential of -4%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3398.25%. Given that Theriva Biologics, Inc. has higher upside potential than Kezar Life Sciences, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Kezar Life Sciences, Inc..

Kezar Life Sciences, Inc. has a beta of 0.505, which suggesting that the stock is 49.462% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.

Kezar Life Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kezar Life Sciences, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.

Kezar Life Sciences, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. Kezar Life Sciences, Inc.'s net income of -$11.2M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Kezar Life Sciences, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kezar Life Sciences, Inc. is -- versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.